Overview
Actively managed equity portfolio investing worldwide in biotech companies.
Efficient means of exploiting the potential of biotech companies operating in research, product development, production or distribution.
Specialised sector analysts seek out the most attractive stocks in the biotech sector worldwide.
Investment decisions are based on a disciplined investment philosophy and fundamental research.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
Benefits
Easy access to the global biotech sector.
Offers investors broad diversification within the sector.
The fund taps into the knowledge of proven sector specialists.
麻豆社's proprietary fundamental valuation approach enables the most attractive biotechnology companies to be consistently identified.
Investors benefit from a global investment platform of 麻豆社 Asset Management.
Risks
Features
| Product category |
麻豆社 Equity Funds 麻豆社 Sector Funds |
| Product domicile |
Luxembourg
|
| Portfolio management |
麻豆社 Asset Management (Americas) LLC, New York
|
| Fund management |
麻豆社 Asset Management (Europe) S.A., Luxembourg
|
| Custodian bank |
麻豆社 Europe SE, Luxembourg Branch
|
| Representative for products established under foreign law |
麻豆社 AG, Stockholm
|
| Day of inception |
October 15, 1996
|
| Currency of account |
USD
|
| Close of financial year |
November 30
|
| SFDR Classification |
Art.8
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
2.12% p.a.
|
| Management fee |
1.63% p.a.
|
| Total expense ratio (TER) |
2.09% p.a.
|
| Swing pricing |
yes
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
MSCI US Investable Market Biotechnology 10/40 Index (r)
|
| ISIN |
LU0069152568
|
| Bloomberg Ticker |
麻豆社EBIO LX
|
| Telekurs Id |
EQBIO
|
Performance and Prices
Percentage growth
as of May 27, 2026| USD(%) | EUR(%) | |
| YTD | ||
| 1M | ||
| 3M | ||
| 6M | ||
| 1Y | 50.78 | 47.08 |
| 2Y | ||
| 3Y | 38.50 | 27.53 |
| 5Y | 21.61 | 27.62 |
| ø p.a.5Y | 3.99 | 5.00 |
Current data
| Net asset value | 27.05.2026 | USD 923.12 |
| High - last 12 months | 24.02.2026 | USD 947.46 |
| Low - last 12 months | 30.05.2025 | USD 616.46 |
| Assets of the unit class in mn | 27.05.2026 | USD 403.53 |
| Total product assets in mn | 27.05.2026 | USD 462.58 |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 30.04.2026 | 15.52% | 17.01% |
| Sharpe Ratio | 30.04.2026 | 0.76 | -0.03 |
| Risk Free Rate | 30.04.2026 | 4.48% | 3.57% |
Structures
By the 10 largest equity positions (in %, as of April 30, 2026)
|
|
|
| Vertex Pharmaceuticals Inc | 9.14 |
| Insmed Inc | 5.28 |
| Ionis Pharmaceuticals Inc | 4.41 |
| Arrowhead Pharmaceuticals Inc | 4.29 |
| Roivant Sciences Ltd | 3.93 |
| AbbVie Inc | 3.68 |
| Amgen Inc | 3.56 |
| Gilead Sciences Inc | 3.54 |
| Royalty Pharma PLC | 3.47 |
| BioNTech SE | 3.41 |
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
| Prospectus |
|
| Country supplement |
|
| Key Information Document |
|
| Past performance |
|
| Previous performance scenario |
|
| Statutes / Management regulations |
|
|
Document type
|
Document Language
|
| Annual report |
|
| Semi-annual report |
|